Scarica l'app Stockscreener
3.3578
26.33%
-1.0922
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
JPMorgan Chase & Co. Acquires 3,093 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (NASDAQ:LXEO) - Seeking Alpha
Lexeo Therapeutics to Present New CMC Data at the 28th - GlobeNewswire
Lexeo Therapeutics Inc Inc. (LXEO) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - The Manila Times
Was anything positive for Lexeo Therapeutics Inc (LXEO) stock last session? - uspostnews.com
Lexeo Therapeutics to Present Data on AAV Manufacturing at ASGCT Annual Meeting - Nasdaq
Insider Selling: Townsend Richard Nolan, Lexeo Therapeutics Inc [LXEO] Chief Executive Officer divested 4,326 shares - knoxdaily.com
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Thursday - Defense World
Analyzing Ocugen (NASDAQ:OCGN) and Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX
Geode Capital Management LLC Has $3.74 Million Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of “Buy” from Brokerages - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025 - CGTLive®
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Bought by Wellington Management Group LLP - Defense World
Chardan Capital Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $22.00 - MarketBeat
Chardan Capital Has Positive Outlook of LXEO FY2025 Earnings - Defense World
Alzheimer's Disease Drug Development Pipeline: 2025-A Surge - openPR.com
Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
Lexeo’s Gene Therapy LX2006 Reduces Abnormal LVMI in Patients With Friedreich Ataxia Cardiomyopathy - CGTLive®
Gene Therapy Shows Promise for Fatal Heart Condition Tied to Friedreich Ataxia - Managed Healthcare Executive
Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc. - TipRanks
Chardan Research Adjusts Lexeo Therapeutics Price Target to $22 From $25, Maintains Buy Rating - marketscreener.com
Lexeo’s Cardiac Gene Therapy Achieves Good Early Trial Results - Inside Precision Medicine
Lexeo Plots Pivotal Path for Friedreich’s Ataxia Gene Therapy After ‘Compelling’ Phase I/II Data - BioSpace
H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock - Investing.com
H.C. Wainwright maintains Buy rating on Lexeo Therapeutics stock By Investing.com - Investing.com UK
Lexeo Therapeutics price target lowered to $22 from $25 at Chardan - TipRanks
Lexeo touts Friedreich ataxia cardiomyopathy candidate as 'best-in-class' - FirstWord Pharma
Lexeo Therapeutics Reports Positive Interim Trial Results - TipRanks
Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers - Endpoints News
Lexeo Therapeutics Says Potential FA Cardiomyopathy Therapy Improves Cardiac Biomarkers - marketscreener.com
Lexeo Therapeutics announces ‘positive’ Interim Phase 1/2 data for LX2006 - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study - MarketScreener
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewswire
Breakthrough Data: Gene Therapy Shows 25% Heart Improvement in Fatal Rare Disease - Stock Titan
Lexeo stock hits 52-week low at $2.31 amid sharp annual decline - Investing.com Canada
Lexeo stock hits 52-week low at $2.31 amid sharp annual decline By Investing.com - Investing.com South Africa
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks - BioPharma Dive
Q1 EPS Estimate for Lexeo Therapeutics Raised by Analyst - The AM Reporter
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Raised by Bank of New York Mellon Corp - Defense World
What is Chardan Capital’s Estimate for LXEO FY2025 Earnings? - Defense World
Q1 EPS Estimate for Lexeo Therapeutics Increased by Analyst - Defense World
HC Wainwright Reaffirms Buy Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
What is Leerink Partnrs’ Forecast for LXEO FY2025 Earnings? - Defense World
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw? - MSN
Analysts Offer Predictions for LXEO Q1 Earnings - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $20.00 at Royal Bank of Canada - Defense World
2 Stocks Riding the Biotech Surge With Major Catalysts Ahead - Investing.com
H.C. Wainwright maintains Buy on Lexeo stock, $23 target By Investing.com - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
H.C. Wainwright maintains Buy on Lexeo stock, $23 target - Investing.com
Lexeo Therapeutics price target lowered to $20 from $24 at RBC Capital - TipRanks
Pharma Frenzy: Volatility Ignites Biotech Sector - Sharewise
6.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):